Eurofins Scientific News More News
Eurofins Scientific Historical Prices
Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period:
0%
0
Eurofins Scientific Analyst Opinions
- All
- Buy
- Hold
- Sell
Eurofins Scientific Estimates* in EUR
2023 | 2024 | 2025 | 2026 | 2027 | |
---|---|---|---|---|---|
Revenue | 6,644 | 7,154 | 7,639 | 8,063 | 8,612 |
Dividend | 0.97 | 1.04 | 1.15 | - | - |
Dividend Yield (in %) | 1.67 % | 1.74 % | 1.89 % | - | - |
EPS | 2.75 | 3.36 | 3.66 | 3.49 | 3.82 |
P/E Ratio | 22.52 | 18.40 | 16.92 | 17.72 | 16.19 |
EBIT | 858 | 978 | 1,085 | - | - |
EBITDA | 1,406 | 1,568 | 1,720 | 1,764 | 1,904 |
Net Profit | 525 | 628 | 718 | - | - |
Net Profit Adjusted | 530 | 662 | 767 | - | - |
Pre-Tax Profit | 761 | 882 | 1,005 | - | - |
Net Profit (Adjusted) | 532 | 689 | 833 | - | - |
EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
EPS (GAAP) | 2.42 | 2.93 | 3.31 | - | - |
Gross Income | 2,942 | 3,174 | 3,406 | - | - |
Cash Flow from Investing | -105 | -172 | -148 | - | - |
Cash Flow from Operations | 1,017 | 1,145 | 1,273 | - | - |
Cash Flow from Financing | -358 | -319 | -537 | - | - |
Cash Flow per Share | 5.69 | 6.34 | 6.94 | - | - |
Free Cash Flow | 483 | 565 | 654 | - | - |
Free Cash Flow per Share | 2.84 | 2.97 | - | - | - |
Book Value per Share | 26.53 | 28.75 | 29.37 | - | - |
Net Debt | 3,097 | 2,985 | 2,805 | - | - |
Research & Development Exp. | - | - | - | - | - |
Capital Expenditure | 560 | 570 | 597 | - | - |
Selling, General & Admin. Exp. | - | - | - | - | - |
Shareholder’s Equity | 4,984 | 5,442 | 5,464 | - | - |
Total Assets | 10,515 | 11,046 | 10,738 | - | - |
Previous Quarter ending 12/31/22 |
Current Quarter | Next Quarter |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 1 | - | 1 | 13 | 13 |
Average Estimate | 1.562 EUR | - | 1.088 EUR | 2.747 EUR | 3.361 EUR |
Year Ago | - | - | - | 3.430 EUR | 2.747 EUR |
Publish Date | 3/1/2023 | - | 8/2/2023 | - | - |
Revenue Estimates | |||||
No. of Analysts | 1 | - | - | 12 | 12 |
Average Estimate | 1,721 EUR | - | - | 6,644 EUR | 7,154 EUR |
Year Ago | - | - | - | 6,712 EUR | 6,644 EUR |
Publish Date | 3/1/2023 | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Eurofins Scientific Dividend Calendar
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2022 | Eurofins Scientific SE | - | - | EUR |
2021 | Eurofins Scientific SE | 1.00 | 0.92 | EUR |
2020 | Eurofins Scientific SE | 0.68 | 0.99 | EUR |
2019 | Eurofins Scientific SE | - | - | EUR |
2018 | Eurofins Scientific SE | 0.29 | 0.88 | EUR |
2017 | Eurofins Scientific SE | 0.24 | 0.47 | EUR |
2016 | Eurofins Scientific SE | 0.20 | 0.49 | EUR |
2015 | Eurofins Scientific SE | 0.14 | 0.45 | EUR |
2015 | Eurofins Scientific SE | 0.15 | 0.44 | EUR |
2014 | Eurofins Scientific SE | 0.13 | 0.62 | EUR |
2013 | Eurofins Scientific SE | 0.12 | 0.61 | EUR |
2012 | Eurofins Scientific SE | 0.10 | 0.82 | EUR |
2011 | Eurofins Scientific SE | 0.08 | 1.42 | EUR |
2010 | Eurofins Scientific SE | 0.01 | 0.19 | EUR |
2010 | Eurofins Scientific SE | 0.02 | 0.37 | EUR |
2009 | Eurofins Scientific SE | 0.10 | 0.26 | EUR |
2008 | Eurofins Scientific SE | 0.01 | 0.28 | EUR |
2007 | Eurofins Scientific SE | 0.01 | 0.13 | EUR |
2006 | Eurofins Scientific SE | 0.01 | 0.18 | EUR |
*Yield of the Respective Date
Eurofins Scientific SE Calendar
Event | Estimate | Info | Date |
---|---|---|---|
Earnings Report | 1.088 EUR | Q2 2023 Earnings Release | 08/02/2023 |
Earnings Report | - | Q4 2023 Earnings Release | 03/05/2024 |
Earnings Report | - | Q2 2024 Earnings Release | 07/31/2024 |
Earnings Report | - | Q4 2024 Earnings Release | 03/11/2025 |
Eurofins Scientific SE Past Events
Event | Actual EPS | Info | Date |
---|---|---|---|
Earnings Report | - | Q4 2022 Earnings Release | 03/01/2023 |
Eurofins Scientific Profile
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.
Moody’s Daily Credit Risk Score
Eurofins Scientific Shareholder
Owner | in % |
---|---|
Freefloat | 66.93 |
Martin Family | 33.05 |
Government Pension Fund - Global (The) | 1.46 |
Sequoia Fund | 1.33 |
Fidelity Series Overseas Fund | 0.89 |
Vanguard Total International Stock Index Fund | 0.84 |
American Funds New Perspective Fund | 0.82 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Eurofins Scientific Management
Name | Job |
---|---|
Gilles G. Martin | Chairman & Chief Executive Officer |
Sandra Hoeylaerts | Chief Human Resource Officer |
Christian Wurst | Chief Operating Officer-Food & Environment Testing |
Laurent Lebras | Director-Group Finance & Administration |
Valérie Hanote | Executive Director |
Ivo Rauh | Independent Non-Executive Director |
Evie Roos | Independent Non-Executive Director |
Féréchté Pouchantchi | Independent Non-Executive Director |
Patrizia Luchetta | Independent Non-Executive Director |
Pascal Rakovsky | Lead Independent Non-Executive Director |
François Vigneau | Managing Director-Food Division Southern Europe |
Yves-Loïc Martin | Non-Executive Director |
Jennifer Ohayon | Sci Dir-Large Mol Bioanlys-Eurofins Bioanalyt Svcs |
Christopher Hervé | Vice President |